tert-butyl-isopentyl ether | 92097-05-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl-isopentyl ether
• 英文别名: tert-Butyl-isopentyl-aether；1,1-Dimethylethyl 3-methylbutyl ether；3-methyl-1-[(2-methylpropan-2-yl)oxy]butane
• CAS: 92097-05-7
• 化学式: C₉H₂₀O
• 分子量: 144.257
• InChiKey: JWIOTWYGCKFGDG-UHFFFAOYSA-N

物化性质

• 沸点：
  140 °C
• 密度：
  0.7662 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  异戊醇 、 异丁烯 在 硫酸 作用下， 生成 tert-butyl-isopentyl ether
  参考文献：
  名称：

  Evans; Edlund, Industrial and Engineering Chemistry, 1936, vol. 28, p. 1188

  摘要：

  DOI：

文献信息

• [EN] AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME<br/>[FR] AGENTS CIBLANT LES AMYLOÏDES ET PROCÉDÉS DE LEUR UTILISATION
  申请人：AMYDIS DIAGNOSTICS

  公开号：WO2015143185A1

  公开（公告）日：2015-09-24

  Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are the methods for treating of diseases associated with an amyloid or amyloid like proteins.

  本文提供了用于检测淀粉样蛋白或类淀粉样蛋白的新型分子转子荧光团的设计和合成。这些荧光团被设计为与淀粉样蛋白或类淀粉样蛋白结合时，与未结合化合物相比表现出增强的荧光发射。本文还披露了用于治疗与淀粉样蛋白或类淀粉样蛋白相关疾病的方法。
• [EN] PROSTACYCLIN DERIVATIVES<br/>[FR] DÉRIVÉS DE PROSTACYCLINE
  申请人：CONCERT PHARMACEUTICALS INC

  公开号：WO2011003058A1

  公开（公告）日：2011-01-06

  This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors.

  本发明涉及新的前列腺素I2衍生物及其可接受的盐。该发明还提供了包含本发明化合物的组合物，以及将这些组合物用于治疗通过前列腺素I2有益治疗的疾病和状况的方法，特别是那些通过全身和肺动脉血管床扩张剂或通过血小板聚集抑制剂有益治疗的疾病和状况。
• [EN] METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS<br/>[FR] MÉTHODES DE TRAITEMENT D'UN SUJET ET PARTICULES, POLYMÈRES ET COMPOSITIONS À CET EFFET
  申请人：FETZER OLIVER S

  公开号：WO2012044832A1

  公开（公告）日：2012-04-05

  Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates.

  本文描述了一种利用聚合物-药剂颗粒和环糊精聚合物药剂共轭物组合治疗受试者的方法。本文中的方法可用于治疗被诊断患有癌症、心血管疾病、自身免疫性疾病或炎症性疾病的受试者。本文还描述了包含聚合物-药剂颗粒和环糊精聚合物药剂共轭物的组合物、剂型和配套工具。
• [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES<br/>[FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS
  申请人：AFASCI INC

  公开号：WO2017083867A1

  公开（公告）日：2017-05-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。
• [EN] POLYMERIC DRUG DELIVERY SYSTEMS FOR TREATMENT OF DISEASE<br/>[FR] SYSTÈMES D'ADMINISTRATION DE MÉDICAMENT POLYMÈRE POUR LE TRAITEMENT D'UNE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2017100533A1

  公开（公告）日：2017-06-15

  Provided are compositions and nanoparticle formulations that may be used, e.g., to deliver a therapeutic compound to a subject. In some embodiments, the nanoparticles may be used to deliver one or more chemotherapeutic agents to treat a cancer such, e.g., as a pancreatic ductal adenocarcinoma.

  提供的是组合物和纳米粒子配方，可用于将治疗化合物输送到受试者体内。在某些实施例中，纳米粒子可用于输送一种或多种化疗药物，以治疗癌症，例如胰腺导管腺癌。